Harry Lamble

Harry has extensive experience in the management of high growth businesses in the life sciences field, having held a number of senior roles in start-up companies.

Previously, he was Director of Business Development and Company Secretary at Oxford BioTherapeutics, an emerging biotech company located in Oxford, UK and San Jose, CA, focused on cancer target / biomarker discovery and the development of novel antibody-based drugs for cancer. While at the company he completed numerous major collaboration and licensing agreements with global biopharmaceutical and diagnostics companies (including GSK, Sanofi, Amgen, BMS, Seattle Genetics, Alere & Menarini).

Harry also has close links to Imperial College’s Institute of Biomedical Engineering, where as Research Development Director, he coordinated multidisciplinary research initiatives in the medical technology field, promoting translation through collaboration with clinical investigators, Imperial Innovations and med-tech companies.

In his earlier career as a research scientist, Harry completed a PhD and post-doctoral research on the industrial application of thermostable enzymes at the University of Bath and worked for companies in the fields of genomics, biomanufacturing and scientific software development. Harry has an MBA from Cranfield School of Management.